By Jared S. Hopkins and Betsy McKay 

A federal advisory panel recommended Wednesday that 12- to 15-year-olds receive the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, an important step toward expanding the nation's vaccination campaign.

The Advisory Committee on Immunization Practices, or ACIP, which advises the Centers for Disease Control and Prevention on vaccination policy, voted to recommend the vaccine at a meeting Wednesday after reviewing clinical trial data and other relevant information. The vote was 14-0, with one voting member recusing.

Vaccinations of adolescents have already begun in some parts of the country, but most vaccination providers were waiting for a formal recommendation from ACIP. A committee recommendation becomes policy when the CDC's director, Dr. Rochelle Walensky, signs it.

Expanding vaccination to children is necessary to slow the spread of Covid-19 and move the country beyond the pandemic, allowing returns to school, work and commerce, public-health officials say.

The 15-member panel consists of pediatricians, infectious-disease doctors and other medical experts. The panel's recommendation follows the Food and Drug Administration's authorization Monday of the two-dose shot for use in children as young as 12 years old, the first Covid-19 vaccine for children in the nation.

Children are at lower risk of Covid-19 infection than adults, according to health experts, and when they are infected, they tend to experience milder symptoms. Yet some children can become seriously ill and some can spread the virus.

At Wednesday's meeting, ACIP members discussed the results of the Pfizer-BioNTech study of 2,260 adolescents that found the two-dose shot was 100% effective at protecting against symptomatic Covid-19 in 12- to 15-year-olds.

In the trial, about half of the subjects received two doses of vaccine three weeks apart, while the rest of the subjects received placebos. The volunteers who got the vaccine received the same dose that older people get.

Researchers found 12- to 15-year-olds who received the vaccine generated an immune response similarly strong as in 16- to 25-year-olds.

So far, researchers haven't found evidence the vaccine poses any additional or different risks to children versus adults. The most common side effects of the vaccine are flulike symptoms such as fever, muscle aches and chills, at similar rates found in 16- to 25-year-olds, according to the CDC and Pfizer.

Seven children who were vaccinated experienced swollen or enlarged lymph nodes due to the vaccine, compared with one subject in the placebo group, according to Pfizer and the CDC.

Five children who received the vaccine experienced serious side effects, compared with two in the placebo group, said John Perez, Pfizer's vice president of clinical research and development. In the vaccinated group these included four cases of psychiatric disorders, including depression, anxiety and suicide ideation, and Dr. Perez said these children either had a history of depression or were prescribed medication for related disorders before the trial. One child experienced stomach pain and constipation, and nerve pain.

None of the serious side effects were found to be linked to the vaccine, according to the CDC.

Pfizer hasn't yet analyzed the data by race or ethnicity, said Dr. Perez. About 85% of the subjects in the trial were white.

There were no deaths in the study, said Dr. Perez. There were no severe allergic reactions or cases of Bell's palsy, which is temporary muscle paralysis in the face that was found in a small number of adults in Pfizer's pivotal study, according to Dr. Perez and the CDC. There also were no cases of blood clots, which have been found in small numbers of people who received other Covid-19 vaccines, Dr. Perez said.

Vaccinating adolescents, along with other groups of the population, is an important step toward making it possible for the U.S. to move beyond the pandemic, said Sara Oliver, a CDC medical officer. Infected children, while less affected by the disease than adults, can transmit the virus to others, studies have shown.

Covid-19 cases are rising in adolescents, and as older Americans have gotten vaccinated, adolescents make up an increasing proportion of the overall U.S. case count, Dr. Oliver said. Adolescents accounted for 9% of reported cases in April, a larger proportion than those reported for people 65 years and older as more adults have been vaccinated, she said.

More than 1.5 million children ages 12 to 17 have been diagnosed with Covid-19 since March 2020 and more than 13,000 have been hospitalized, CDC data show. Millions of cases go unreported, though, Dr. Oliver said. The agency estimates that 22.2 million children ages 5 to 17 have been infected since February 2020, making up about 19% of all infections.

Hospitalizations among 12- to 17-year-olds are far higher for Covid-19 than for influenza, CDC data show, and adolescents suffer more severely from a rare Covid-19 complication known as multisystem inflammatory syndrome in children, or MIS-C, than younger children. Covid-19 made up 1.3% of all deaths among 12- to 17-year-olds between Jan. 1, 2020, and April 30 this year. That level would have put it in the top 10 causes of death among children in 2019, Dr. Oliver said.

The Pfizer-BioNTech shot has become the most widely used shot in the U.S. since regulators cleared it in December for use in people 16 years and older after a trial involving 44,000 subjects. More than 1 million Americans who are under age 18 have received the vaccine, according to the CDC.

The Pfizer-BioNTech vaccine is among three authorized for use in the U.S., along with shots from Moderna Inc. and Johnson & Johnson.

Covid-19 vaccines for children under 12 years may be available in the U.S. by the end of the year. Pfizer anticipates asking the FDA in September to authorize its vaccine's use in children 2 to 11 years old should ongoing studies prove positive. It plans to make a similar request for children 6 months to 2 years of age in the fourth quarter, Pfizer said.

Write to Jared S. Hopkins at jared.hopkins@wsj.com and Betsy McKay at betsy.mckay+1@wsj.com

 

(END) Dow Jones Newswires

May 12, 2021 15:40 ET (19:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.